• Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events
  • Advertise
  • About Us
Home
  • Biotech
    • Cell & Gene Therapy
    • Clinical Data
    • Venture Capital
    • Deals
  • Research
  • Medtech
    • Devices
    • Diagnostics
    • AI and Machine Learning
  • CRO
  • Special Reports
  • Trending
    • Biologics
    • Clinical Development
  • Fierce 50
    • Special Report
    • Awards Gala
  • Awards
    • CRO Awards
    • Innovation Awards
  • Resources
    • Fierce Events
    • Industry Events
    • Webinars
    • Podcasts
    • Whitepapers
    • Survey
  • Events
  • Subscribe
Home
Trending
Hamburger Menu Hamburger Menu
  • Biotech
    • Cell & Gene Therapy
    • Clinical Data
    • Venture Capital
    • Deals
  • Research
  • Medtech
    • Devices
    • Diagnostics
    • AI and Machine Learning
  • CRO
  • Special Reports
  • Trending
    • Biologics
    • Clinical Development
  • Fierce 50
    • Special Report
    • Awards Gala
  • Awards
    • CRO Awards
    • Innovation Awards
  • Resources
    • Fierce Events
    • Industry Events
    • Webinars
    • Podcasts
    • Whitepapers
    • Survey
  • Events
  • Subscribe
  • Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events
  • Advertise
  • About Us

bladder cancer

White arrow on a road pointing to the rising sun
Biotech

Pfizer ties PD-1 drug to 32% cancer risk reduction in phase 3

The study fell short of a clean sweep, with Pfizer finding no effect on survival and seeing a higher rate of serious adverse events in the PD-1 arm.
Nick Paul Taylor Apr 28, 2025 7:25am
cancer target detection radiopharma radio

Acrivon stops testing Lilly castoff for ovarian, bladder cancer

Mar 26, 2025 7:05am
Soccer ball flying into a net scoring a goal

Pfizer's PD-1 prospect hits goal in phase 3 bladder cancer study

Jan 10, 2025 6:45am
gold arrow pointing upward forward

Protara shares spike after bladder cancer data drop

Dec 5, 2024 2:30pm
Doctor examining red diagram of urinary system

With ph. 1 data, Aura has an eye on early-stage bladder cancer

Oct 17, 2024 4:05pm
Stop sign

J&J stops phase 3 bladder cancer trial after interim review flop

Oct 8, 2024 4:58am

Home
  • Connect
    • The Team
    • Advertise
    • Marketing Kit
    • Let's Talk
  • Join Us
    • Newsletters
    • Resources
    • RSS Feeds
  • Our Brands
    • Fierce Pharma
    • Fierce Biotech
    • Fierce Healthcare
  • Our Events
    • Life Sciences Events
©2025 Questex LLC All rights reserved.
Terms of use
Privacy Policy
Privacy Settings